Some previous studies have revealed the enhanced treatment response rate and survival outcome in patients with a high level of tissue-based TMB who receive ICIs in lung cancer.[8] In this study, the MN patient with stage IV LSCC had high PD-L1 expression (20%) and high TMB level (26.2 mutations/Mb), which indicated that the patient might benefit from ICIs. This evidence concerns the gene CD274 and lung cancer.